Bio-ADM as a Biomarker of Refilling in Chronic Hemodialysis Patient

NCT05339009 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2022-04-21

No results posted yet for this study

Summary

Aim of this study is to evaluate in a population of chronic kidney disease patients on dialysis (Stage 5D) the predictive value of bio-adrenomedullin (bio-ADM) level on vascular refilling rate.

Conditions

  • Chronic Kidney Disease 5D

Interventions

BIOLOGICAL

BioADM determination in plasma

BioADM determination in plasma

Sponsors & Collaborators

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Jean-Paul CRISTOL, MD PhD · University Hospital Center of Montpellier, FRANCE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2022-12-31
Completion
2023-05-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05339009 on ClinicalTrials.gov